Releasing the brake: Restoring fast axonal transport in neurodegenerative disorders

Trends in Cell Biology

Volumn 23, Issue 12, 2013, Pages 634-643

  Hinckelmann, Maria Victoria ^a,b   Zala, Diana ^a,b   Saudou, Frédéric ^a,b  

^a INSTITUT CURIE   (France)

^b INSERM U1005   (France)

Author keywords

Dynein; Kinesin; Microtubules; Organelles; Therapies; Trafficking

Indexed keywords

ALPHA TUBULIN; AMYLOID PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CALCINEURIN; CYTOPLASMIC DYNEIN; DYNACTIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HEAT SHOCK PROTEIN 27; HISTONE DEACETYLASE; HISTONE DEACETYLASE 6; HUNTINGTIN; KINESIN; KINESIN 1; MITOFUSIN 2; MOLECULAR MOTOR; NEUROTROPHIN 3; PARKIN; PRESENILIN 1; SPASTIN; STRESS ACTIVATED PROTEIN KINASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BINDING AFFINITY; CELL ORGANELLE; CELL SURVIVAL; CITRIC ACID CYCLE; DEGENERATIVE DISEASE; DENDRITE; DIMERIZATION; DISEASE COURSE; ENDOCYTOSIS; EXON; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HIPPOCAMPAL NEURONAL CULTURE; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; INTRACELLULAR TRANSPORT; MICROTUBULE; MISSENSE MUTATION; MITOCHONDRION; MOTOR NEUROPATHY; MUSCLE ATROPHY; MUSCLE CONTRACTION; MUSCLE REINNERVATION; MUTATIONAL ANALYSIS; NERVE ENDING; NERVE FIBER TRANSPORT; NEUROMUSCULAR SYNAPSE; NEUROPROTECTION; NONHUMAN; NONSENSE MUTATION; PAIRED HELICAL FILAMENT; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PERRY SYNDROME; PHENOTYPE; POINT MUTATION; POLARIZATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETT SYNDROME; REVIEW; SPINAL MUSCULAR ATROPHY; WILD TYPE;

DYNEIN; KINESIN; MICROTUBULES; ORGANELLES; THERAPIES; TRAFFICKING;

AXONAL TRANSPORT; ENERGY METABOLISM; HUMANS; MICROTUBULES; MOLECULAR MOTOR PROTEINS; MUTATION; NEURODEGENERATIVE DISEASES;

EID: 84888199555     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2013.08.007     Document Type: Review

References (96)

1. Hirokawa N., et al. Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. Neuron 2010, 68:610-638.
2. Millecamps S., Julien J-P. Axonal transport deficits and neurodegenerative diseases. Nat. Rev. Neurosci. 2013, 14:161-176.
3. Zhao C., et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell 2001, 105:587-597.
4. Reid E., et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am. J. Hum. Genet. 2002, 71:1189-1194.
5. Ebbing B., et al. Effect of spastic paraplegia mutations in KIF5A kinesin on transport activity. Hum. Mol. Genet. 2008, 17:1245-1252.
6. Twelvetrees A.E., et al. Delivery of GABAARs to synapses is mediated by HAP1-KIF5 and disrupted by mutant huntingtin. Neuron 2010, 65:53-65.
7. Klebe S., et al. KIF1A missense mutations in SPG30, an autosomal recessive spastic paraplegia: distinct phenotypes according to the nature of the mutations. Eur. J. Hum. Genet. 2012, 20:645-649.
8. Erlich Y., et al. Exome sequencing and disease-network analysis of a single family implicate a mutation in KIF1A in hereditary spastic paraparesis. Genome Res. 2011, 21:658-664.
9. Harms M.B., et al. Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophy. Neurology 2012, 78:1714-1720.
10. Weedon M.N., et al. Exome sequencing identifies a DYNC1H1 mutation in a large pedigree with dominant axonal Charcot-Marie-Tooth disease. Am. J. Hum. Genet. 2011, 89:308-312.
11. Puls I., et al. Mutant dynactin in motor neuron disease. Nat. Genet. 2003, 33:455-456.
12. Farrer M.J., et al. DCTN1 mutations in Perry syndrome. Nat. Genet. 2009, 41:163-165.
13. Lloyd T.E., et al. The p150(Glued) CAP-Gly domain regulates initiation of retrograde transport at synaptic termini. Neuron 2012, 74:344-360.
14. Moughamian A.J., Holzbaur E.L.F. Dynactin is required for transport initiation from the distal axon. Neuron 2012, 74:331-343.
15. Gauthier L.R., et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
16. Caviston J.P., et al. Huntingtin facilitates dynein/dynactin-mediated vesicle transport. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10045-10050.
17. Colin E., et al. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J. 2008, 27:1-11.
18. Zala D., et al. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum. Mol. Genet. 2008, 17:3837-3846.
19. Gunawardena S., et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003, 40:25-40.
20. Li S.H., et al. Interaction of huntingtin-associated protein with dynactin P150Glued. J. Neurosci. 1998, 18:1261-1269.
21. McGuire J.R., et al. Interaction of huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons. J. Biol. Chem. 2006, 150:3552-3559.
22. Roux J-C., et al. Modification of Mecp2 dosage alters axonal transport through the huntingtin/Hap1 pathway. Neurobiol. Dis. 2011, 45:786-795.
23. Godin J.D., et al. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 2010, 67:392-406.
24. Keryer G., et al. Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease. J. Clin. Invest. 2011, 121:4372-4382.
25. Cosker K.E., et al. Action in the axon: generation and transport of signaling endosomes. Curr. Opin. Neurobiol. 2008, 18:270-275.
26. Humbert S., et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2002, 2:831-837.
27. Pineda J.R., et al. Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease. Mol. Brain 2009, 11:1-11.
28. Deinhardt K., et al. Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron 2006, 52:293-305.
29. Verhoeven K., et al. Mutations in the small GTPase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am. J. Hum. Genet. 2003, 72:722-727.
30. Zhang K., et al. Defective axonal transport of Rab7 GTPase results in dysregulated trophic signaling. J. Neurosci. 2013, 33:7451-7462.
31. Janke C., Kneussel M. Tubulin post-translational modifications: encoding functions on the neuronal microtubule cytoskeleton. Trends Neurosci. 2010, 33:362-372.
32. Dixit R., et al. Differential regulation of dynein and kinesin motor proteins by tau. Science 2008, 319:1086-1089.
33. Dumanchin C., et al. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum. Mol. Genet. 1998, 7:1825-1829.
34. Zhang B., et al. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J. Neurosci. 2004, 24:4657-4667.
35. Wagner U., et al. Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J. Cell Sci. 1996, 109:1537-1543.
36. Bull N.D., et al. Reduced axonal transport and increased excitotoxic retinal ganglion cell degeneration in mice transgenic for human mutant P301S tau. PLoS ONE 2012, 7:e34724.
37. Shahpasand K., et al. Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease. J. Neurosci. 2012, 32:2430-2441.
38. Hazan J., et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat. Genet. 1999, 23:296-303.
39. Blackstone C., et al. Hereditary spastic paraplegias: membrane traffic and the motor pathway. Nat. Rev. Neurosci. 2011, 12:31-42.
40. Chaturvedi R.K., Beal M.F. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol. Cell. Neurosci. 2013, 55:101-114.
41. Zala D., et al. Vesicular glycolysis provides on-board energy for fast axonal transport. Cell 2013, 152:479-491.
42. Kennerson M.L., et al. A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is caused by mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene. Hum. Mol. Genet. 2013, 22:1404-1416.
43. Xu W-Y., et al. A nonsense mutation in DHTKD1 causes Charcot-Marie-Tooth disease type 2 in a large Chinese pedigree. Am. J. Hum. Genet. 2012, 91:1088-1094.
44. Morfini G., et al. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 2002, 21:281-293.
45. Xu J., et al. Casein kinase 2 reverses tail-independent inactivation of kinesin-1. Nat. Commun. 2012, 3:754.
46. Chua J.J.E., et al. Phosphorylation-regulated axonal dependent transport of syntaxin 1 is mediated by a kinesin-1 adapter. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:5862-5867.
47. Manser C., et al. Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo. Oncogene 2012, 31:2773-2782.
48. Vagnoni A., et al. Phosphorylation of kinesin light chain 1 at serine 460 modulates binding and trafficking of calsyntenin-1. J. Cell Sci. 2011, 124:1032-1042.
49. Guillaud L., et al. Disruption of KIF17-Mint1 interaction by CaMKII-dependent phosphorylation: a molecular model of kinesin-cargo release. Nat. Cell Biol. 2008, 10:19-29.
50. Horiuchi D., et al. Control of a kinesin-cargo linkage mechanism by JNK pathway kinases. Curr. Biol. 2007, 17:1313-1317.
51. Morfini G.A., et al. Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat. Neurosci. 2009, 12:864-871.
52. Drerup C.M., Nechiporuk A.V. JNK-interacting protein 3 mediates the retrograde transport of activated c-Jun N-terminal kinase and lysosomes. PLoS Genet. 2013, 9:e1003303.
53. Mehan S., et al. JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. J. Mol. Neurosci. 2011, 43:376-390.
54. Pardo R., et al. Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J. Neurosci. 2006, 26:1635-1645.
55. Metzler M., et al. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J. Neurosci. 2010, 30:14318-14329.
56. Ben M'barek K., et al. Huntingtin mediates anxiety/depression-related behaviors and hippocampal neurogenesis. J. Neurosci. 2013, 33:8608-8620.
57. d'Ydewalle C., et al. HDAC6 at the intersection of neuroprotection and neurodegeneration. Traffic 2012, 13:771-779.
58. Reed N.A., et al. Microtubule acetylation promotes kinesin-1 binding and transport. Curr. Biol. 2006, 16:2166-2172.
59. Dompierre J.P., et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 2007, 27:3571-3583.
60. Chen S., et al. HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS ONE 2010, 5:e10848.
61. Hempen B., Brion J.P. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1996, 55:964-972.
62. Bobrowska A., et al. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. PLoS ONE 2011, 6:e20696.
63. Taes I., et al. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum. Mol. Genet. 2013, 22:1783-1790.
64. Kim C., et al. HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons. PLoS ONE 2012, 7:e42983.
65. Govindarajan N., et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol. Med. 2013, 5:52-63.
66. Xiong Y., et al. HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:4604-4609.
67. Simões-Pires C., et al. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?. Mol. Neurodegener. 2013, 8:7.
68. Zhang B., et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 2012, 32:3601-3611.
69. Barten D.M., et al. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J. Neurosci. 2012, 32:7137-7145.
70. Lovas J.R., Wang X. The meaning of mitochondrial movement to a neuron's life. Biochim. Biophys. Acta 2013, 1833:184-194.
71. Ding W-X., Yin X-M. Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol. Chem. 2012, 393:547-564.
72. Chen X-J., et al. Proprioceptive sensory neuropathy in mice with a mutation in the cytoplasmic dynein heavy chain 1 gene. J. Neurosci. 2007, 27:14515-14524.
73. Hafezparast M., et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 2003, 300:808-812.
74. Kieran D., et al. A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J. Cell Biol. 2005, 169:561-567.
75. Teuling E., et al. A novel mouse model with impaired dynein/dynactin function develops amyotrophic lateral sclerosis (ALS)-like features in motor neurons and improves lifespan in SOD1-ALS mice. Hum. Mol. Genet. 2008, 17:2849-2862.
76. Perlson E., et al. A switch in retrograde signaling from survival to stress in rapid-onset neurodegeneration. J. Neurosci. 2009, 29:9903-9917.
77. Allan V.J. Cytoplasmic dynein. Biochem. Soc. Trans. 2011, 39:1169-1178.
78. Pfister K.K., et al. Genetic analysis of the cytoplasmic dynein subunit families. PLoS Genet. 2006, 2:e1.
79. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
80. Braathen G.J., et al. MFN2 point mutations occur in 3.4% of Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT families. BMC Med. Genet. 2010, 11:48.
81. Chapman A.L., et al. Axonal transport defects in a mitofusin 2 loss of function model of Charcot-Marie-Tooth disease in zebrafish. PLoS ONE 2013, 8:e67276.
82. Lazarov O., et al. Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J. Neurosci. 2007, 27:7011-7020.
83. Gunawardena S., et al. Presenilin controls kinesin-1 and dynein function during APP-vesicle transport in vivo. Hum. Mol. Genet. 2013, 22:3828-3843.
84. Wang X., et al. PINK1 and Parkin target miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 2011, 147:893-906.
85. Brownlees J., et al. Charcot-Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. Hum. Mol. Genet. 2002, 11:2837-2844.
86. Pérez-Ollé R., et al. Mutations in the neurofilament light gene linked to Charcot-Marie-Tooth disease cause defects in transport. J. Neurochem. 2005, 93:861-874.
87. LaMonte B.H., et al. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002, 34:715-727.
88. Zuccato C., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 2003, 35:76-83.
89. Brito V., et al. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies. Cell Death Dis. 2013, 4:e595.
90. Ginés S., et al. Impaired TrkB-mediated ERK1/2 activation in Huntington disease knock-in striatal cells involves reduced p52/p46 Shc expression. J. Biol. Chem. 2010, 285:21537-21548.
91. Liot G., et al. Mutant huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J. Neurosci. 2013, 33:6298-6309.
92. Bilsland L.G., et al. Deficits in axonal transport precede ALS symptoms in vivo. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20523-20528.
93. Amano T., et al. Production of nerve growth factor in rat skeletal muscle. Neurosci. Lett. 1991, 132:5-7.
94. Zhao C., et al. NGF, BDNF, NT-3, and GDNF mRNA expression in rat skeletal muscle following denervation and sensory protection. J. Neurotrauma 2004, 21:1468-1478.
95. Fanara P., et al. Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. J. Clin. Invest. 2012, 122:3159-3169.
96. Inoue T., et al. Manganese enhanced MRI (MEMRI): neurophysiological applications. Rev. Neurosci. 2011, 22:675-694.